PVLA Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Palvella Therapeutics (PVLA) is a strong buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company has demonstrated exceptional Phase 3 trial results for its lead asset, QTORIN rapamycin, which positions it well for FDA approval and strong market adoption. Despite the pre-market price dip of -2.43%, the stock's technical indicators remain bullish, and analysts have significantly raised price targets, reflecting high confidence in the company's growth potential. The recent upsized public offering further strengthens its financial position to advance its pipeline.
The technical indicators for PVLA are bullish. The MACD is positive and expanding (7.395), RSI is overbought at 95.536, and moving averages are aligned in a bullish pattern (SMA_5 > SMA_20 > SMA_200). The stock is trading above key pivot levels, with resistance at R2: 154.166 and support at S1: 80.986. Despite the pre-market dip, the overall trend remains strong.
Exceptional Phase 3 SELVA trial results for QTORIN rapamycin, achieving statistical significance in primary and secondary endpoints.
Analysts have significantly raised price targets, with multiple firms maintaining Buy or Outperform ratings.
Upsized public offering of $200 million strengthens financial resources for pipeline development.
High probability of FDA approval for QTORIN rapamycin, with strong market potential in orphan skin diseases.
Pre-market price drop of -2.43%, which may indicate short-term volatility.
Overbought RSI (95.536), suggesting potential for a short-term pullback.
In 2025/Q3, the company reported no revenue growth (0% YoY) and a net income loss of -$11.35 million, though this improved by 62.79% YoY. EPS declined to -1.03 (-73.86% YoY). While financials are weak, the company's focus on clinical development and recent capital raise mitigate concerns for long-term investors.
Analysts are overwhelmingly positive on PVLA, with multiple firms raising price targets significantly following the Phase 3 SELVA trial results. Price targets now range from $190 to $255, reflecting high confidence in the company's growth trajectory and potential FDA approval for QTORIN rapamycin.
